|
Avaliação DCF da Immunome, Inc. (IMNM)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Immunome, Inc. (IMNM) Bundle
Projetado para precisão, a calculadora DCF da Immunome, Inc. (IMNM) permite avaliar a avaliação do imunoma usando dados financeiros do mundo real, oferecendo flexibilidade completa para modificar todos os parâmetros essenciais para melhorar as projeções.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -9.7 | -17.0 | -23.9 | -36.3 | -28.3 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| EBITDA, % | 100 | 100 | 100 | 100 | -201.68 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .6 | .8 | .8 | .6 | .7 | 11.4 | 11.4 | 11.4 | 11.4 | 11.4 |
| Depreciation, % | 100 | 100 | 100 | 100 | 5.19 | 81.04 | 81.04 | 81.04 | 81.04 | 81.04 |
| EBIT | -10.3 | -17.8 | -24.7 | -36.9 | -29.0 | 8.4 | 8.4 | 8.4 | 8.4 | 8.4 |
| EBIT, % | 100 | 100 | 100 | 100 | -206.87 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 2.5 | 39.8 | 49.2 | 20.3 | 138.1 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .9 | 4.3 | .8 | .3 | 11.3 | 11.3 | 11.3 | 11.3 | 11.3 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 2.06 | 80.41 | 80.41 | 80.41 | 80.41 | 80.41 |
| Inventories | .0 | -.9 | -4.3 | -.8 | .0 | 11.2 | 11.2 | 11.2 | 11.2 | 11.2 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | .5 | 1.2 | 3.1 | 2.4 | 3.3 | 11.9 | 11.9 | 11.9 | 11.9 | 11.9 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 23.62 | 84.72 | 84.72 | 84.72 | 84.72 | 84.72 |
| Capital Expenditure | -.2 | -.6 | -.1 | -.2 | -.8 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -5.93 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -10.4 | -17.1 | -24.5 | -37.5 | -29.0 | 8.3 | 8.3 | 8.3 | 8.3 | 8.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -9.5 | -16.2 | -21.9 | -37.8 | -28.5 | 5.9 | 19.5 | 19.5 | 19.5 | 19.5 |
| WACC, % | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 | 12.94 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 56.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 20 | |||||||||
| Terminal Value | 182 | |||||||||
| Present Terminal Value | 99 | |||||||||
| Enterprise Value | 156 | |||||||||
| Net Debt | -97 | |||||||||
| Equity Value | 253 | |||||||||
| Diluted Shares Outstanding, MM | 20 | |||||||||
| Equity Value Per Share | 12.74 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real IMNM financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effects of your inputs on Immunome’s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Data Access: Immunome’s historical financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Monitor Immunome’s intrinsic value recalculating instantly.
- Intuitive Visualizations: Dashboard charts present valuation outcomes and essential metrics clearly.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Download the Template: Gain immediate access to the Excel-based IMNM DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Immunome’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Immunome, Inc. (IMNM)?
- Precision: Utilizes real Immunome financial data to ensure accuracy.
- Adaptability: Built for users to easily adjust and test various inputs.
- Efficiency: Eliminate the need to create a DCF model from the ground up.
- Expert-Level: Crafted with the precision and usability expected by CFOs.
- Accessible: Intuitive interface suitable for users without extensive financial modeling knowledge.
Who Should Use This Product?
- Investors: Accurately assess Immunome, Inc.’s (IMNM) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immunome, Inc. (IMNM).
- Consultants: Efficiently modify the template for valuation reports tailored to Immunome, Inc. (IMNM) clients.
- Entrepreneurs: Acquire insights into the financial modeling practices employed by leading biotech firms like Immunome, Inc. (IMNM).
- Educators: Employ it as a teaching resource to illustrate valuation methodologies relevant to Immunome, Inc. (IMNM).
What the Template Contains
- Historical Data: Includes Immunome, Inc.'s (IMNM) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Immunome, Inc.'s (IMNM) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Immunome, Inc.'s (IMNM) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.